Yaron Brook, chairman of the Ayn Rand Institute and host of the Yaron Brook Show, joins Niklas to discuss the moral and philosophical foundations of capitalism.

They explore Ayn Rand’s philosophy of Objectivism, the ethical case for individual freedom, and why capitalism is often misunderstood in modern political discourse. The conversation also touches on libertarian governance, free private cities, and what a truly free society could look like in practice.

A deep dive into capitalism, philosophy, and the future of human freedom.

In this episode, he and Niklas explore how genome sequencing, DNA synthesis, and CRISPR are turning life into an engineering platform. From coding proteins and viruses to writing entire genomes, Andrew explains how biotech is moving from reading DNA to actively programming it.

They discuss N-of-1 personalized therapies, biosecurity in an age of cheap DNA synthesis, and why open science could accelerate biotech innovation. The conversation also touches on cloning, embryo editing, and the long-term future of human enhancement.

Topics include:

· DNA as digital code · Genome writing and synthetic cells · CRISPR and programmable biology · Personalized genetic medicine · Biosecurity and engineered viruses · Open biotech vs. proprietary models · Cloning and human genome design

A conversation for builders, founders, and technologists thinking about biology as the next software layer.

In this episode, she and Niklas explore why drug development takes over a decade, why only ~10% of drugs reach approval, and how clinical trials have become one of the biggest bottlenecks to biomedical progress.

They unpack how incentives distort which diseases get treated, why surrogate endpoints matter, and how off-label use, real-world data, and even “bro science” reveal gaps in the current system.

They also cover: • Clinical evolution and iterative human testing • Regulatory opacity and open-sourcing FDA filings • Australia’s faster Phase 1 model • Human challenge trials and medical freedom • Surrogate endpoints and distorted incentives • Real-world data and off-label discovery • Biotech innovation shifting to China • How better trials unlock biomedical abundance

A conversation for anyone interested in biotech, policy, and the future of drug development.